Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Grants Emergency Use Authorization To Variety Of OTC COVID-19 Tests

Executive Summary

The US agency has granted emergency use authorization to consumer COVID-19 testing products from Quidel, Abbott and BD.

You may also be interested in...



NIH, CDC Distributing OTC COVID-19 Tests In US Study On Reducing Community Transmission

NIH pays for 2 million Quidel QuickVue tests in a program it is conducting with the CDC to determine whether frequent self-administered testing helps reduce community transmission of SARS-CoV-2.

Abbott Receives US Authorization For First 'Virtually Guided' At-Home Rapid Test

Abbott plans to deliver 30 million BinaxNOW prescription, at-home rapid tests in the first quarter of 2021; 90 million more in the second quarter.

Prescience Point Capital Launches Proxy Fight To Change MiMedx's Board

Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current board has destroyed shareholder value. The company's tock is selling for about a third of its potential value, according to Prescience.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel